
|Articles|November 25, 2014
- Immunotherapy (Issue 4)
- Volume 4
- Issue 1
Immunotherapies for Prostate Cancer
Author(s)William K. Oh, MD
William K. Oh, MD, discusses immunotherapies for the treatment of patients with prostate cancer.
Advertisement
William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses immunotherapies for the treatment of patients with prostate cancer.
<<<
Articles in this issue
about 11 years ago
To Combine or Sequence Anti-PD-1 and Anti-PD-L1 in Questionabout 11 years ago
Programs Prepare for Immuno-Oncology in Clinical Settingabout 11 years ago
Right Patient for Immunotherapy in NSCLC Exploredabout 11 years ago
Weight May Affect Toxicity of Immunotherapiesabout 11 years ago
Adverse Events Associated With Immunotherapy in Lung Cancerabout 11 years ago
Immunotherapy Potential Option in Mesothelioma Treatmentabout 11 years ago
Potential Immunotherapies for Head and Neck CancersAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















